Go Pro

Extendicare (TSE:EXE) Trading Down 8.3% - Here's Why

Extendicare logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Extendicare shares fell 8.3% to C$31.35, with trading volume nearly doubling the daily average to about 745,218 shares.
  • Analysts remain positive, with a consensus “Buy” rating and several upgraded price targets ranging as high as C$40.00; the consensus target is C$32.56.
  • The company reported quarterly revenue of C$611.04 million and EPS of C$0.32, while announcing a monthly dividend of C$0.0441 per share, representing a 1.7% yield.
  • MarketBeat previews the top five stocks to own by September 1st.

Extendicare Inc. (TSE:EXE - Get Free Report) was down 8.3% during trading on Friday . The stock traded as low as C$30.57 and last traded at C$31.35. Approximately 745,218 shares traded hands during mid-day trading, an increase of 95% from the average daily volume of 383,111 shares. The stock had previously closed at C$34.19.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on EXE. National Bank Financial increased their price target on shares of Extendicare from C$34.00 to C$40.00 and gave the company an "outperform" rating in a report on Wednesday, May 27th. Canaccord Genuity Group raised shares of Extendicare to a "strong-buy" rating in a research report on Monday, May 11th. TD increased their target price on shares of Extendicare from C$32.00 to C$39.00 and gave the company a "buy" rating in a research note on Monday, May 11th. Desjardins set a C$34.50 target price on Extendicare and gave the stock a "buy" rating in a research report on Wednesday, April 22nd. Finally, BMO Capital Markets upped their price target on Extendicare from C$30.00 to C$38.00 in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. Based on data from MarketBeat.com, Extendicare currently has a consensus rating of "Buy" and a consensus price target of C$32.56.

View Our Latest Report on Extendicare

Extendicare Price Performance

The stock has a market cap of C$3.01 billion, a P/E ratio of 23.36 and a beta of 1.59. The company has a current ratio of 1.44, a quick ratio of 0.98 and a debt-to-equity ratio of 82.55. The company's fifty day simple moving average is C$35.24 and its 200-day simple moving average is C$30.18.

Extendicare (TSE:EXE - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported C$0.32 earnings per share for the quarter. Extendicare had a net margin of 6.99% and a return on equity of 45.35%. The business had revenue of C$611.04 million for the quarter. As a group, sell-side analysts forecast that Extendicare Inc. will post 0.6134729 EPS for the current year.

Extendicare Announces Dividend

The business also recently announced a monthly dividend, which will be paid on Monday, August 17th. Stockholders of record on Monday, August 17th will be issued a $0.0441 dividend. The ex-dividend date of this dividend is Friday, July 31st. This represents a c) dividend on an annualized basis and a dividend yield of 1.7%. Extendicare's dividend payout ratio is presently 37.24%.

Extendicare Company Profile

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines